Faculty profile

Ofer Agid

Back to faculty

Associate ProfessorDepartment of PsychiatryUniversity of Toronto

Ofer Agid

Associate Professor

Department of Psychiatry

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
14 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

3,344

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Closing the medication gap at the prison gate.
Evidence-based nursing · 2026 · first author
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.
The American journal of psychiatry · 2025
Antipsychotic discontinuation in schizophrenia: rational or reckless?
Schizophrenia (Heidelberg, Germany) · 2025

All 88 publications

Latest funding

Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing
CIHR · 2019 · Co-investigator
$856,800
Magnetic Seizure Therapy for Schizophrenia (MAST) - Trial
CIHR · 2019 · Co-investigator
$898,876
Imaging synaptic density in schizophrenia
CIHR · 2018 · Co-investigator
$531,675

All 6 grants and awards

88 publications.

Closing the medication gap at the prison gate.

Agid O

Evidence-based nursing2026First author

DOI: 10.1136/ebnurs-2026-104734 PMID: 42711108

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

Howes OD, Bukala BR, Chen EYH, Correll CU, Hasan A, Honer WG, Kane JM, Leucht S, Siafis S, Agid O, Akena D, Arango C, Atwoli L, Barnes TRE, Birnbaum ML, Bitter I, Breier A, Buchanan RW, Citrome L, Cotter DR, Crossley N, Davidson M, de Bartolomeis A, DeLisi LE, Dollfus S, Dursun SM, Ebdrup BH, Elkis H, Emsley R, Falkai P, Fernández-Egea E, Fleischhacker W, Freudenreich O, Gadelha A, Gaebel W, Graff-Guerrero A, Gridley A, Hallak JEC, Homan P, Kahn RS, Kaiser S, Kapi M, Kennedy JL, Kim E, Kinon BJ, Soo Kwon J, Lawrie SM, Lee J, Leweke FM, Li T, Libiger J, Marder SR, Melle I, Meltzer H, Mucci A, Naber D, Nakajima S, Nielsen J, O'Brien O, Ojagbemi A, Omlor W, Pantelis C, Peuskens J, Raedler TJ, Ran MS, Marques TR, Remington G, Rossell S, Rubio JM, Sachs G, Scott J, Si T, Siskind D, Siu CO, Sommer IE, Suzuki T, Takeuchi H, Tandon R, Taylor D, Teferra S, Thomas N, Tiihonen J, Uchida H, Ucok A, Umbricht D, Venkatasubramanian G, Wagner E, Walters JTR, Wang C, Weiser M, Wright C, Yu X, McCutcheon RA

The American journal of psychiatry202513 citations

DOI: 10.1176/appi.ajp.20241040 PMID: 41058236

Antipsychotic discontinuation in schizophrenia: rational or reckless?

Zipursky RB, Agid O, Remington G

Schizophrenia (Heidelberg, Germany)20252 citationsOpen Access

DOI: 10.1038/s41537-025-00698-8 PMID: 41407711

Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée.

Zipursky RB, Agid O, Kiang M, Remington G

Canadian journal of psychiatry. Revue canadienne de psychiatrie20251 citationsOpen Access

DOI: 10.1177/07067437241295648 PMID: 39544022

Challenges for switching central nervous system and psychiatric medication products: A review of the literature

Ric M. Procyshyn, Martin A. Katzman, Howard C. Margolese, Ofer Agid, Pierre M Blier

Journal of Psychopharmacology20251 citationsOpen Access

DOI: 10.1177/02698811241301219 PMID: 39886775

The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.

Kane JM, Agid O, Castle DJ, Citrome L, Fagiolini A, Kishimoto T, Larrauri CA, Leucht S, Rubio JM, Sajatovic M, Schooler N, Correll CU

Neurology and therapy2025

DOI: 10.1007/s40120-025-00838-3 PMID: 41057718

Placebo versus no treatment for people with schizophrenia: A systematic review and meta-analysis.

Nomura N, Shimomura Y, Kikuchi Y, Hird E, Wu H, Agid O, Leucht S, Takeuchi H

PCN reports : psychiatry and clinical neurosciences2025

DOI: 10.1002/pcn5.70214 PMID: 41069661

Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder

Roger S. McIntyre, Ofer Agid, Egbert Biesheuvel, Pradeep Purushottamahanti

CNS Spectrums202413 citationsOpen Access

DOI: 10.1017/s1092852924000245 PMID: 38685594

Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment.

Agid O

Expert review of neurotherapeutics2024First author

DOI: 10.1080/14737175.2024.2365943 PMID: 38879827

Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.

Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Seppälä N, Correll CU

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2024First author

DOI: 10.1016/j.euroneuro.2024.04.012 PMID: 38657339

Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing

Co-investigatorCIHR2019Project Grant

Principal investigators: Remington, Gary

Keywords: Clinical Research

$856,800

Magnetic Seizure Therapy for Schizophrenia (MAST) - Trial

Co-investigatorCIHR2019Project Grant

Principal investigators: Daskalakis, Zafiris J; Foussias, George

Keywords: Cognition; Electroconvulsive Therapy (Ect); Magnetic Seizure Therapy (Mst); Neurophysiology; Neuroplasticity; Randomized Control Trial (Rct); Treatment Resistant Schizophrenia (Trs)

$898,876

Imaging synaptic density in schizophrenia

Co-investigatorCIHR2018Project Grant

Principal investigators: Mizrahi, Romina

Keywords: Biomarker; Molecular Imaging; Positron Emission Tomography; Schizophrenia; Synaptic Density; Synaptic Pruning

$531,675

Clozapine Levels, Clinical Response, and Side Effects

Co-investigatorCIHR2013Operating Grant

Principal investigators: Remington, Gary

Keywords: Clozapine; Clozapine Levels; Clozapine Response; Clozapine Side Effects; Schizophrenia; Therapeutic Drug Monitoring; Treatment Resistant Schizophrenia

$442,650

Imaging the Limbic Dopamine D3 receptor in Schizophrenia

Co-investigatorCIHR2011Operating Grant

Principal investigators: Graff-Guerrero, Ariel; Mamo, David C

Keywords: D3; Dopamine System; Positron Emission Tomography; Schizophrenia; [11c]-(+)-Phno

$168,366

Patterns of Antipsychotic Nonadherence: Impact on Treatment Outcome

Co-investigatorCIHR2010Pfizer Operating Grant in Disease Prevention and Management

Principal investigators: Remington, Gary

Keywords: Antipsychotic Dose; Antipsychotic Nonadherence; Antipsychotic Side Effects; Antipsychotics; Outcome; Schizophrenia

$92,539

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Ofer Agid

Research

Latest papers

Latest funding

Closing the medication gap at the prison gate.

Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.

Antipsychotic discontinuation in schizophrenia: rational or reckless?

Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corr&#xe9;lats cliniques des concentrations plasmiques de palip&#xe9;ridone &#xe0; lib&#xe9;ration prolong&#xe9;e.

Challenges for switching central nervous system and psychiatric medication products: A review of the literature

The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment.

Placebo versus no treatment for people with schizophrenia: A systematic review and meta-analysis.

Effect of venlafaxine on anhedonia and amotivation in patients with major depressive disorder

Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment.

Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice.

Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing

Magnetic Seizure Therapy for Schizophrenia (MAST) - Trial

Imaging synaptic density in schizophrenia

Clozapine Levels, Clinical Response, and Side Effects

Imaging the Limbic Dopamine D3 receptor in Schizophrenia

Patterns of Antipsychotic Nonadherence: Impact on Treatment Outcome

Frequent collaborators

Gary Remington

George Foussias

Ariel Graff-Guerrero

Konstantine Zakzanis

Maggie Hahn

Margaret Hahn

David Castle

Arun Ravindran

Aristotle Voineskos

Philip Gerretsen

Eric Brown

Kyle Daniell

Christopher Tsoutsoulas

Naima Javaid

Sri Agarwal

Michael Kiang

Mark Sinyor

Araba Chintoh

Mahavir Agarwal

Vina Goghari

Ric Procyshyn

William Honer

Serdar Dursun

Paula Goering

Romina Mizrahi

Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée.